Exchange & Returns Information
Review Details
(0)
| Generic For | SPRYCEL |
|---|---|
| Active Ingredient | DASATINIB |
| Strength | 50MG |
| Manufacturer | ZYDUS CADILA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 60 TABLETS | $ 1.17 | $ 70.00 |
$ 59.50
Apply ZARVY26 (-15%)
You save $ 10.50
|
||
| 2 BOXES - 120 TABLETS | $ 1.23 | $ 148.00 |
$ 125.80
Apply ZARVY26 (-15%)
You save $ 22.20
|
||
| ★ Best Value 3 BOXES - 180 TABLETS | $ 1.26 | $ 226.00 |
$ 192.10
Apply ZARVY26 (-15%)
You save $ 33.90
|
Reference information will be available soon.
Spnib 50 is a generic formulation of dasatinib indicated for the treatment of Philadelphia chromosome–positive (Ph+) leukemias, particularly chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (Ph+ ALL). As a second-generation tyrosine kinase inhibitor (TKI), it blocks the BCR-ABL fusion protein as well as SRC-family kinases, providing broader and more potent suppression of leukemic proliferation compared to first-generation agents such as imatinib.
Spnib 50 is effective even in advanced disease stages and is recognized for its ability to penetrate the central nervous system (CNS), making it suitable for patients with CNS involvement.
AntiCancer Drugs > Chronic Myeloid Leukemia (CML)
Spnib 50 is approved for use in Ph+ CML across all stages—chronic, accelerated, and blast crisis. It is particularly valuable for patients who have developed resistance or intolerance to first-line therapy with imatinib. By targeting BCR-ABL and SRC kinases, it promotes rapid hematologic and cytogenetic responses, helping to delay disease progression.
> Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Spnib 50 is used as monotherapy or in combination with chemotherapy for treating relapsed or refractory Ph+ ALL. Its ability to cross the blood–brain barrier makes it useful in managing or preventing CNS infiltration. It also serves as an effective bridge therapy before hematopoietic stem cell transplantation (HSCT).
> Myeloid & Lymphoid Blast Crisis
In patients with CML who have progressed to blast crisis, Spnib 50 may induce rapid cytogenetic responses. It is often employed as part of intensive treatment regimens aimed at regaining disease control or preparing for transplant.
Inhibits BCR-ABL fusion protein and SRC-family kinases
Effective against most imatinib-resistant mutations
Demonstrates rapid hematologic and cytogenetic response
Penetrates the CNS for improved management of leukemic meningitis
Applicable across multiple disease phases and age groups
1. Adult Dose – Leukemia
Chronic Phase CML: 100 mg orally once daily
Accelerated Phase CML / Blast Phase CML / Ph+ ALL: 140 mg orally once daily
Duration: Treatment should be continued until disease progression or unacceptable toxicity. Monitoring for hematologic toxicity, pleural effusion, and cardiac health is advised. Dose modification may be required depending on tolerance or laboratory abnormalities.
2. Pediatric Dose – Leukemia
10–<20 kg: 40 mg orally once daily
20–<30 kg: 60 mg orally once daily
30–<45 kg: 70 mg orally once daily
≥45 kg: 100 mg orally once daily
Notes: Weight-based dosing should be reassessed regularly. In Ph+ ALL, Spnib 50 should be initiated by Day 15 of induction chemotherapy and continued for up to 2 years. This formulation is not recommended for children weighing under 10 kg due to tablet size limitations.
Store at 15–30°C (59–86°F) in a cool, dry environment away from moisture and direct sunlight. Keep the tablets in their original blister packaging. Do not crush or chew tablets; handle with care if broken. Keep out of reach of children.
- Common: fatigue, headache, nausea, diarrhea - Hematologic: neutropenia, anemia, thrombocytopenia - Respiratory: pleural effusion, cough, shortness of breath - Cardiovascular: QT prolongation, peripheral edema - CNS: dizziness, mild cognitive disturbances - Others: skin rash, elevated liver enzymes
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
